. 2019 Nov 10;9(11):e032969. doi: 10.1136/bmjopen-2019-032969

Table 1.

Primary outcomes and methods assessments

Outcome category	Themes evaluated	Data source	Time points
Clinical	Number and thickness of melanomas (including in situ) found.	Clinical records and pathology reports.	0, 6, 12, 18 and 24 months
Clinical	Skin excisions/biopsies and the histopathological categorisations.	Clinical records and pathology reports.	0, 6, 12, 18 and 24 months
Economic	Participant healthcare services utilisation relating to skin surveillance and management.	Participant claims through the Medicare Benefits Schedule and Pharmaceutical Benefits Scheme.	One-off extraction capturing the entire study period of 0–24 months
Economic		Queensland Hospital Admitted Patient Data Collection database, the Healthcare Purchasing and System Performance data and the Health Service Funding Models.
Consumer	Satisfaction and acceptability	Self-administered, validated questionnaire²⁷ adapted from the Technology Acceptance Model.^{28 29} Additional questions will capture satisfaction with travel, waiting times, appointment length, convenience and perceived financial value of the surveillance programme. Recruitment and retention will contribute to analysis.	0 and 24 months
	Health behaviours	Self-administered, validated questionnaire adapted from QSkin study to capture sun protective behaviours and relevant demographics.³⁰	0, 6, 12, 18 and 24 months
	Psychological well-being	Euro-QoL-5D,³¹ to capture quality of life index for the health economic assessment.	0, 6, 12, 18 and 24 months
	Health beliefs	The validated Health Beliefs Survey^{32 33} to evaluate knowledge, perceived severity of melanoma, perceived personal risk and perceived worthiness of surveillance programmes.	0, 6, 12, 18 and 24 months